Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Taylor, David J ^a   Parsons, Christine E ^a   Han, Haiyong ^b   Jayaraman, Arul ^c   Rege, Kaushal ^a  

^a AZ 85281   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Texas A and M University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; ARSENIC; ASPARAGINASE; CHLORAMBUCIL; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FUMAGILLIN; GEFITINIB; GEMCITABINE; GOLD; HYDROXYUREA; IDARUBICIN; IRINOTECAN; LOMUSTINE; MITHRAMYCIN; MITOXANTRONE; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; THIOUREA; TIOGUANINE; TOREMIFENE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MONOTHERAPY; PANCREAS CANCER; PROSTATE CANCER; CELL SURVIVAL; DRUG EFFECT; FEMALE; MALE; PANCREAS TUMOR; PROSTATE TUMOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 80055050352     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-470     Document Type: Article

References (54)

1. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12(3):228-237. 10.1038/sj.cgt.7700792, 15550937.
2. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14(3-4):337-348. 10.1016/S1359-6101(03)00029-7, 12787570.
3. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 2002, 13(3):199-207. 10.1016/S1359-6101(02)00006-0, 12486874.
4. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005, 10(1):35-51. 10.1007/s10495-005-6060-0, 15711921.
5. Fiorucci G, Vannucchi S, Chiantore MV, Percario ZA, Affabris E, Romeo G. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential. Curr Pharm Des 2005, 11(7):933-944. 10.2174/1381612053381729, 15777244.
6. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004, 4(4):333-339. 10.1016/j.coph.2004.02.006, 15251125.
7. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004, 16(2):139-144. 10.1016/j.cellsig.2003.08.007, 14636884.
8. Sheikh MS, Fornace AJ. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000, 14(8):1509-1513. 10.1038/sj.leu.2401865, 10942251.
9. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004, 95(10):777-783. 10.1111/j.1349-7006.2004.tb02181.x, 15504243.
10. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002, 62(20):5800-5806.
11. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003, 63(17):5390-5400.
12. Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 2006, 66(10):5363-5370. 10.1158/0008-5472.CAN-05-4386, 16707463.
13. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001, 299(1):31-38.
14. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7(4):383-385. 10.1038/86397, 11283636.
15. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006, 12(8):2640-2646. 10.1158/1078-0432.CCR-05-2635, 16638878.
16. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999, 59(11):2747-2753.
17. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000, 19(40):4604-4610. 10.1038/sj.onc.1203816, 11030149.
18. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000, 35(6):608-611. 10.1002/1096-911X(20001201)35:6<608::AID-MPO25>3.0.CO;2-U, 11107128.
19. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000, 60(16):4315-4319.
20. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate. cancer Oncogene 2001, 20(42):6073-6083.
21. White SJ, Lu P, Keller GM, Voelkel-Johnson C. Targeting the Short Form of cFLIP by RNA Interference is Sufficient to Enhance TRAIL Sensitivity in PC3 Prostate Carcinoma Cells. Cancer Biol Ther 2006, 5(12):1618-1623. 10.4161/cbt.5.12.3352, 17106251.
22. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21(15):2283-2294. 10.1038/sj.onc.1205258, 11948412.
23. Kim MR, Lee JY, Park MT, Chun YJ, Jang YJ, Kang CM, Kim HS, Cho CK, Lee YS, Jeong HY, et al. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 2001, 505(1):179-184. 10.1016/S0014-5793(01)02816-2, 11557065.
24. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004, 61(1):35-49. 10.1002/pros.20069, 15287092.
25. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003, 22(13):2034-2044. 10.1038/sj.onc.1206290, 12673208.
26. Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 2001, 24(6):459-471. 10.1097/00002371-200111000-00003, 11759069.
27. Barua S, Linton RS, Gamboa J, Banerjee I, Yarmush ML, Rege K. Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists. Cancer Lett 2010, 293(2):240-253. 10.1016/j.canlet.2010.01.012, 20347216.
28. Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000, 19(39):4513-4522. 10.1038/sj.onc.1203810, 11002424.
29. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004, 64(19):7086-7091. 10.1158/0008-5472.CAN-04-1498, 15466204.
30. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006, 2(8):415-416. 10.1038/nchembio806, 16816845.
31. Abramoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics International 2004, 11(7):36-42.
32. Papadopulos F, Spinelli M, Valente S, Foroni L, Orrico C, Alviano F, Pasquinelli G. Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastructural Pathology 2007, 31(4-6):401-407.
33. Jones DT, Ganeshaguru K, Mitchell WA, Foroni L, Baker RJ, Prentice HG, Mehta AB, Wickremasinghe RG. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. British journal of haematology 2003, 121(5):713-720. 10.1046/j.1365-2141.2003.04340.x, 12780785.
34. Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, Terachi T, Ogawa O. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. International journal of oncology 2002, 20(5):949-954.
35. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer research 1999, 59(24):6153-6158.
36. Meinhold-Heerlein I, Borges-Engeby K, Grunn U, Bauerschlag D, Maass N, Mundhenke C, Jonat W, Bauknecht T. TRAIL-induced apoptosis of ovarian cancer cell lines with selective drug resistance. Geburtshilfe und Frauenheilkunde 2005, 65(11):1064-1073.
37. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006, 5(11):2737-2746. 10.1158/1535-7163.MCT-06-0426, 17121920.
38. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. Bmc Cancer 2005, 5:2. 10.1186/1471-2407-5-2, 546011, 15638938.
39. Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther 2003, 2(3):283-290.
40. Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP. Predominant Bcl-XL Knockdown Disables Antiapoptotic Mechanisms: Tumor Necrosis Factor'ÄìRelated Apoptosis-Inducing Ligand'ÄìBased Triple Chemotherapy Overcomes Chemoresistance in Pancreatic Cancer Cells In vitro. Cancer Research 2005, 65(6):2344-2352. 10.1158/0008-5472.CAN-04-3502, 15781649.
41. Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Research 2003, 23(1A):251-258.
42. Barua S, Rege K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small (Weinheim an der Bergstrasse, Germany) 2009, 5(3):370-376.
43. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M. Dna Topoisomerase Ii-Mediated Interaction of Doxorubicin and Daunorubicin Congeners with Dna. Cancer research 1989, 49(21):5969-5978.
44. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002, 1(5):520-527. 10.4161/cbt.1.5.174, 12496481.
45. Kim KH, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clinical Cancer Research 2000, 6(2):335-346.
46. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer research 1999, 59(3):734-741.
47. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radical Biology and Medicine 2007, 43(9):1313-1321. 10.1016/j.freeradbiomed.2007.06.015, 2084083, 17893044.
48. Northrop G, Taylor SG, Northrop RL. Biochemical Effects of Mithramycin on Cultured Cells. Cancer research 1969, 29(11):1916.
49. Miller DM, Polansky DA, Thomas SD, Ray R, Campbell VW, Sanchez J, Koller CA. Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci 1987, 294(5):388-394. 10.1097/00000441-198711000-00015, 2962490.
50. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004, 63(12):S15-S18.
51. Valenti M, Cimoli G, Mariani GL, Conte PF, Parodi S, Russo P. Potentiation of Tnf-Mediated Cell-Killing by Mitoxantrone - Relationship to Dna Single-Strand Break Formation. Biochemical pharmacology 1993, 46(7):1199-1206. 10.1016/0006-2952(93)90468-C, 8216370.
52. Noviello E, Cimoli G, Cosimi A, Allievi E, Galletti P, Parodi S, Russo P. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine 1996, 8(4):330-333. 10.1006/cyto.1996.0045, 9162224.
53. Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han HY, Von Hoff DD. Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clinical Cancer Research 2009, 15(21):6519-6528. 10.1158/1078-0432.CCR-09-0077, 2783218, 19861455.
54. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, Tsao MS. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000, 157(5):1623-1631. 10.1016/S0002-9440(10)64800-6, 1885733, 11073822.